App-Quantinova.ai

Real-world experience of dose tapering TNF inhibitors in rheumatoid arthritis: Long-term results

May Nwe Lwin - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Harnessing quantitative proteomics to identify biomarkers of treatment response to etanercept in patients with rheumatoid arthritis

Stephanie F Ling - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Etanercept

Association of clinical and demographic factors with quality of life, functional status, depression, and fatigue in patients presenting with, and at risk of, rheumatoid arthritis

Barbara Torlinska - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Harnessing high throughput multiplex immunoassays and protein association networks to identify diagnostic protein biomarkers of rheumatoid arthritis-cardiovascular disease (RA-CVD) multimorbid axis

Rudresh Shukla - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions

Maya H Buch - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Filgotinib

Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis

Christopher P Denton - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

AX-202

JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications

Christopher Stovin - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

ABT-494

Trends for opioid prescriptions and the impact of the COVID-19 pandemic among patients with rheumatic and musculoskeletal diseases between 2006 and 2021

Yun-Ting (Joyce) Huang - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Lupus

Morphine

Factors associated with long-term opioid use in fibromyalgia patients newly started on an opioid: results from Clinical Practice Research Datalink

Mengyu Feng - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Fibromyalgia

Epimorph

Juvenile Sjögren’s syndrome is characterised by dysregulated of B and T memory cell frequencies: a pilot immunophenotyping analysis of this rare disease phenotype

Lucia Martin-Gutierrez - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

N/A

Non-steroidal anti-inflammatory drugs reduce sacroiliac joint inflammation in axial spondyloarthritis

Gareth T Jones - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

IL-13 inhibition used for atopic diseases is associated with risk of psoriatic arthritis

Sizheng Steven Zhao - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ankylosing spondylitis

tralokinumab

Identification of surrogate serum proteomic biomarkers associated with ultrasound power Doppler in psoriatic arthritis

Ryan M Hum - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Patient values and what matters to patients with axial spondyloarthritis in clinic

Antoni Chan - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Smoking and high BMI are associated with reductions in TNF inhibitor response in psoriatic arthritis: results from 12 European countries

Gareth T Jones - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Psoriatic arthritis

N/A

Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELY

Mark D Russell - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Axial spondyloarthritis

N/A

Differences in management approaches for lupus nephritis within the UK

Sara T Ibrahim - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus nephritis

N/A

Use of the patient activation measure in rheumatology outpatients

Claire R Wood - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anxiety

N/A

Management of haemophagocytic lymphohistiocytosis: service evaluation of a national multi-disciplinary meeting

Neal S Shah - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hemophagocytic lymphohistiocytosis

N/A

Improving the biopsychosocial assessment and management of patients with fibromyalgia: developing a digital pre-clinic assessment tool

Ahmad Saif - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Fibromyalgia

N/A

Filters

45280 Abstracts